Business Wire

MAXION-WHEELS

10.9.2019 10:02:10 CEST | Business Wire | Press release

Share
ZF OPENMATICS and Maxion Wheels Partner on Wheel Connectivity Solution

Maxion Wheels, the world’s largest wheel manufacturer, announced today it is collaborating with ZF OPENMATICS to develop the industry’s first, fully-integrated wheel connectivity solution. Initially, targeting the commercial vehicle market, the multiservice sensor will capture, analyze and broadcast key data such as tire pressure and temperature, wheel load and other wheel and tire performance metrics to drivers, fleet managers, and infrastructure authorities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005112/en/

“As a result of the unique load sensor attached to the wheel, the tire and wheel information collected and communicated via the Smart Wheel Connectivity Solution will enable a variety of new safety and efficiency use and business cases,” said Pieter Klinkers, Chief Executive Officer, Maxion Wheels. “By partnering with ZF OPENMATICS we combine our wheel leadership with their intelligent sensing and telematics expertise to offer an integrated mechanical and sensing solution that will help prevent potentially dangerous and costly tire and wheel-end failures, as well as, provide drivers and fleet managers with critical vehicle performance data needed to optimize their business.”

“ZF has the benefit of years of experience with wireless communication like BLE (Bluetooth Low Energy). We are now combining this expertise with that of Maxion to create the world’s first fully integrated battery-powered Wheel TAG sensor that add important functionalities beyond tire pressure monitoring. The benefits of real-time wheel monitoring solutions are being extended to tire life and optimal tire performance. This is another step in the direction of improving road safety, driving comfort and cost efficiency,” said Thomas Rösch, Managing Director ZF OPENMATICS.

The Smart Wheel Connectivity Solution combines Maxion Wheels’ MaxSmart® wheel sensor technology with ZF OPENMATICS’ integrated TAG sensor platform. Mounted directly to each wheel rim of the vehicle, the durable Bluetooth tags track humidity, tire temperature, air pressure and vehicle load as well as wheel position, speed and vibration across nine axis. Information is collected real time and wirelessly transmitted to the vehicle’s telematics onboard unit before being transferred to the ZF Cloud. The data can then be read and analyzed via PC, smart devices or sent to a 3rd party system of the customer’s choice. By fully integrating each different data sensor into one easy-to-use TAG, ZF and Maxion offer unparalleled, true 360° monitoring possibilities.

This fully-integrated system can be installed on virtually all kinds of commercial vehicles and even in agricultural machinery. It provides unique, at-first glance insights, helping to enhance road safety and decrease costs. This makes it highly valuable not only for fleet operators but also mobility providers for autonomous driving solutions.

The new partnership presents its first prototype during the 2019 IAA motor show with the goal to complete its feasibility studies during the first half of 2020, followed by real-world testing and validation.

ABOUT MAXION WHEELS

Maxion Wheels, a division of IOCHPE-MAXION S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks and trailers. The Company also produces wheels for agriculture, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion Wheels is the world's largest wheel manufacturer, producing nearly 60 million wheels per year. It serves its global OEM customers from 31 locations in 15 countries on five continents, including state-of-the-art technical centers in the Americas, Europe and Asia. To learn more, please visit Maxion Wheels’ website at www.maxionwheels.com .

ABOUT ZF FRIEDRICHSHAFEN AG

ZF is a global technology company and supplies systems for passenger cars, commercial vehicles and industrial technology, enabling the next generation of mobility. With its comprehensive technology portfolio, the company offers integrated solutions for established vehicle manufacturers, mobility providers and start-up companies in the fields of transportation and mobility. ZF continually enhances its systems in the areas of digital connectivity and automation in order to allow vehicles to see, think and act.

In 2018, ZF achieved sales of €36.9 billion. The company has a global workforce of 149,000 with approximately 230 locations in 40 countries. ZF invests over six percent of its sales in research and development annually.

Link:

ClickThru

Social Media:

https://www.facebook.com/maxionwheelsofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye